Sophiris Bio (SPHS) Given a $6.00 Price Target by HC Wainwright Analysts

Sophiris Bio (NASDAQ:SPHS) has been given a $6.00 price objective by analysts at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 164.32% from the company’s previous close.

A number of other brokerages also recently issued reports on SPHS. Maxim Group set a $6.00 price target on Sophiris Bio and gave the stock a “buy” rating in a research report on Monday, October 2nd. ValuEngine raised Sophiris Bio from a “strong sell” rating to a “sell” rating in a research report on Friday, December 15th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $6.25.

Shares of Sophiris Bio (NASDAQ:SPHS) opened at $2.27 on Wednesday. The stock has a market capitalization of $68.95, a P/E ratio of -17.46 and a beta of 2.03. Sophiris Bio has a 12-month low of $1.80 and a 12-month high of $3.24. The company has a debt-to-equity ratio of 0.60, a quick ratio of 13.37 and a current ratio of 13.37.

Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.01). analysts forecast that Sophiris Bio will post -0.26 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of SPHS. Boxer Capital LLC acquired a new stake in Sophiris Bio during the fourth quarter worth approximately $1,780,000. Rock Springs Capital Management LP acquired a new stake in Sophiris Bio during the fourth quarter worth approximately $1,138,000. Oxford Asset Management acquired a new stake in Sophiris Bio during the fourth quarter worth approximately $491,000. Mesirow Financial Investment Management Inc. acquired a new stake in shares of Sophiris Bio in the 2nd quarter valued at $120,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Sophiris Bio in the 3rd quarter valued at $100,000. 5.47% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Sophiris Bio (SPHS) Given a $6.00 Price Target by HC Wainwright Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/17/sophiris-bio-sphs-given-a-6-00-price-target-by-hc-wainwright-analysts.html.

About Sophiris Bio

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply